Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of BOTOX in Pediatric Neurogenic Detrusor Overactivity
2012-004898-30Phase 3Completed
- Sponsor
- Allergan
- Start
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in detrusor hyperreflexia (DH) and urinary incontinence (UI), sponsored by Allergan. Primary endpoint: Daytime urinary incontinence episodes. Started Mar 2013; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
detrusor hyperreflexia (DH)urinary incontinence (UI)
Beyond the preview
Go deeper on 2012-004898-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004898-30.